Literature DB >> 8514604

Clonal analysis of multiple point mutations in the N-ras gene in patients with acute myeloid leukemia.

K Kubo1, T Naoe, H Kiyoi, H Fukutani, Y Kato, T Oguri, S Yamamori, Y Akatsuka, Y Kodera, R Ohno.   

Abstract

We have screened mutations of the N-ras gene at codons 12, 13, and 61 in leukemia cells obtained from 100 patients with acute myeloid leukemia (AML), and found mutated N-ras alleles in 9 patients. We further analyzed the polyclonality of multiple N-ras gene mutations in 4 AML patients. One patient, who had the monoclonal karyotype, t(11;17), had two types of double missense mutations at codons 13 and 61 in the same allele. Each of the remaining three patients, one of whom had t(15;17) with a monoclonal rearrangement of the retinoic acid receptor alpha and PML genes, carried two missense mutations in a relatively small population of leukemia cells. We have demonstrated that multiple clonality of the N-ras gene is occasionally observed in leukemia with a monoclonal karyotype. These findings indicate that the N-ras mutations may not always be characterized simply by an accumulative process and that the activated N-ras gene alone is not sufficient to cause leukemia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8514604      PMCID: PMC5919305          DOI: 10.1111/j.1349-7006.1993.tb00147.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  26 in total

1.  Loss of multiple point mutations of RAS genes associated with acquisition of chromosomal abnormalities during disease progression in myelodysplastic syndrome.

Authors:  T Nakagawa; S Saitoh; S Imoto; M Itoh; M Tsutsumi; K Hikiji; Y Nakao; T Fujita
Journal:  Br J Haematol       Date:  1991-02       Impact factor: 6.998

2.  Detection of high incidence of K-ras oncogenes during human colon tumorigenesis.

Authors:  K Forrester; C Almoguera; K Han; W E Grizzle; M Perucho
Journal:  Nature       Date:  1987 May 28-Jun 3       Impact factor: 49.962

3.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

4.  N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance.

Authors:  J P Radich; K J Kopecky; C L Willman; J Weick; D Head; F Appelbaum; S J Collins
Journal:  Blood       Date:  1990-08-15       Impact factor: 22.113

5.  Activation of ras oncogenes preceding the onset of neoplasia.

Authors:  R Kumar; S Sukumar; M Barbacid
Journal:  Science       Date:  1990-06-01       Impact factor: 47.728

6.  Analysis of RAS gene mutations in acute myeloid leukemia by polymerase chain reaction and oligonucleotide probes.

Authors:  C J Farr; R K Saiki; H A Erlich; F McCormick; C J Marshall
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

7.  A dot-blot screening procedure for mutated ras oncogenes using synthetic oligodeoxynucleotides.

Authors:  M Verlaan-de Vries; M E Bogaard; H van den Elst; J H van Boom; A J van der Eb; J L Bos
Journal:  Gene       Date:  1986       Impact factor: 3.688

8.  A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome.

Authors:  H Hirai; Y Kobayashi; H Mano; K Hagiwara; Y Maru; M Omine; H Mizoguchi; J Nishida; F Takaku
Journal:  Nature       Date:  1987 Jun 4-10       Impact factor: 49.962

9.  Frequency and types of point mutation at the 12th codon of the c-Ki-ras gene found in pancreatic cancers from Japanese patients.

Authors:  M Mariyama; K Kishi; K Nakamura; H Obata; S Nishimura
Journal:  Jpn J Cancer Res       Date:  1989-07

10.  Cytogenetic and cellular characteristics of a human embryonal rhabdomyosarcoma cell line, RMS-YM.

Authors:  K Kubo; T Naoe; K R Utsumi; Y Ishiguro; K Ueda; H Shiku; K Yamada
Journal:  Br J Cancer       Date:  1991-06       Impact factor: 7.640

View more
  7 in total

1.  Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance.

Authors:  James A McCubrey; Linda S Steelman; Richard A Franklin; Steven L Abrams; William H Chappell; Ellis W T Wong; Brian D Lehmann; David M Terrian; Jorg Basecke; Franca Stivala; Massimo Libra; Camilla Evangelisti; Alberto M Martelli
Journal:  Adv Enzyme Regul       Date:  2007-03-26

2.  Comparison of the immunoglobulin heavy-chain complementarity determining region-3 structure among the DNA sequences and the mu- and gamma-transcripts in human B-lineage cells.

Authors:  H Kiyoi; H Mori; K Horibe; R Ohno; T Naoe
Journal:  Immunology       Date:  1996-11       Impact factor: 7.397

3.  K-ras gene mutation in gall bladder carcinomas and dysplasia.

Authors:  T Ajiki; T Fujimori; H Onoyama; M Yamamoto; S Kitazawa; S Maeda; Y Saitoh
Journal:  Gut       Date:  1996-03       Impact factor: 23.059

4.  Oncogenic K-ras cooperates with PML-RAR alpha to induce an acute promyelocytic leukemia-like disease.

Authors:  Iris T Chan; Jeffery L Kutok; Ifor R Williams; Sarah Cohen; Sandra Moore; Hirokazu Shigematsu; Timothy J Ley; Koichi Akashi; Michelle M Le Beau; D Gary Gilliland
Journal:  Blood       Date:  2006-05-04       Impact factor: 22.113

5.  Comparable profiles of the immunoglobulin heavy chain complementarity determining region (CDR)-3 in CD5+ and CD5- human cord blood B lymphocytes.

Authors:  H Kiyoi; K Naito; R Ohno; T Naoe
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

Review 6.  Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia.

Authors:  Soheil Meshinchi; Franklin O Smith; Robert J Arceci
Journal:  Curr Oncol Rep       Date:  2003-11       Impact factor: 5.075

Review 7.  The process of leukemogenesis.

Authors:  R D Irons; W S Stillman
Journal:  Environ Health Perspect       Date:  1996-12       Impact factor: 9.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.